compounded glp 1 GLP-1 Training & Drug Information – Hayden's Pharmacy Navigating GLP-1 Antagonist Shortages and

This guidance follows the FDAs approval of Wegovy (semaglutide) for an expanded indication to reduce the risk of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established cardiovascular disease (CVD) and who are either obese or overweight

[DOI] [PubMed] [Google Scholar] 519.Grasset E., Puel A., Charpentier J., Collet X., Christensen J.E., Terce F

Considering that OSAS patients often present with multiple comorbiditiessuch as hypertension, coronary artery disease, and diabetesfurther large-scale, long-term follow-up studies are needed to clarify tirzepatides safety in multimorbid populations (63, 64)

Mechanism In response to a previous FDA inquiry, two short-term mechanical studies were conducted using exenatide and liraglutide in a diabetic rat model, wherein one rat administered with exenatide died of pancreatic necrosis, while the others exhibited acinar-to-ductal metaplasia and ductal hyperplasia, indicative of potential premalignant alterations [62,63]

Francesca Celletti, a senior WHO adviser on obesity, agreed